▲ bullish
Impact
PhasePhase 3
Time to marketIf Phase 3 trials succeed, a New Drug Application submission could occur in 2028-2029, with potential FDA approval and launch in 2029-2030 for the IPF chronic cough indication, assuming standard review timelines.
Haduvio nalbuphine extended-release Updated Nov 12
What to watch
The next major catalyst is topline data from the Phase 3 OCEAN-1 trial in IPF-related chronic cough, expected in 2027. Positive data would validate the Phase 2b signal and likely drive the stock toward the $28 mean analyst target; negative data would be a severe blow given Haduvio is Trevi's only pipeline asset. A Phase 2 start in non-IPF ILD chronic cough is planned for Q1 2027, and the cash runway into 2030 eliminates near-term financing risk.
Bull case
- Haduvio met its primary endpoint in the Phase 2b CORAL trial (N=165) for IPF-related chronic cough, with results published in JAMA in January 2026, providing strong peer-reviewed validation of the mechanism.
- GSK discontinued its rival chronic cough drug camlipixant in July 2026 after a Phase 3 failure, leaving Trevi as the only active developer in its three targeted chronic cough indications and removing a major competitive threat.
- Analyst consensus is Strong Buy (17 Buy/Strong Buy, 1 Hold, 0 Sell) with a mean price target of $28.18, implying roughly 90% upside from the current $14.81 price; BMO Capital has a $36 target.
Bear case
- Haduvio is an opioid-based therapy (kappa agonist / mu antagonist), which carries regulatory, abuse-liability and safety-perception risks that could limit commercial adoption or draw FDA scrutiny.
- Phase 3 trials are inherently binary; positive Phase 2 data does not guarantee Phase 3 success, and the OCEAN-1/OCEAN-2 readouts in 2027-2028 are the only value-defining catalysts for this single-asset company.
- Insider sales by director Michael Heffernan in September 2026 (about $594K total at ~$15/share, via a 10b5-1 plan) and institutional trims by Viking Global (-52% of position) and Citadel (full exit) in Q2 2026 signal some profit-taking near the stock's 52-week high.